The Dermatology Digest

DECEMBER 27, 2024

Johnson & Johnson has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), from Kaken Pharmaceutical.

Dermatitis 36

Dermatitis Portfolios Pharmaceutical Innovations 36

The Dermatology Digest

OCTOBER 28, 2024

Food and Drug Administration (FDA) for treatment of mild, moderate, and severe plaque psoriasis in adults. We are excited to bring this nonbiologic non-steroidal topical option to the millions of patients suffering from a chronic skin condition like plaque psoriasis and, potentially in the future, atopic dermatitis.” “I

Portfolios 36

Portfolios Dermatitis Office Partnerships 36

The Dermatology Digest

MARCH 5, 2024

Pharmacokinetic (PK) data showed a half-life of approximately 75 days across doses tested and pharmacodynamic (PD) data showed, deep and sustained inhibition of key atopic dermatitis (AD) biomarkers pSTAT6 and TARC for ~3 months (longest follow-up available, with inhibition still ongoing at time of the data cut).

Injections 36

Injections Safety Sustainability Clinic 36

The Dermatology Digest

FEBRUARY 26, 2025

Food and Drug Administration (FDA) accepted Arcutis Supplemental New Drug Application (sNDA) for roflumilast cream 0.05% (Zoryve) for the treatment of children aged 2 to 5 with mild-to-moderate atopic dermatitis (AD). The Prescription Drug User Fee Act (PDUFA) target action date is set for October 13, 2025. At Week 4, 25.4%

Safety 36

Safety Dermatitis Portfolios Clinic 36